Cargando…

Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment

In this meta-analysis, we aimed to estimate and compare the efficacy of add-on treatment of antidepressants with esketamine nasal spray and second-generation antipsychotics in patients with nonpsychotic major depressive disorder and inadequate response to antidepressants. Searching for acute-phase,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dold, Markus, Bartova, Lucie, Kasper, Siegfried
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387762/ https://www.ncbi.nlm.nih.gov/pubmed/32570275 http://dx.doi.org/10.1093/ijnp/pyaa034

Ejemplares similares

Clinical Usefulness of Amisulpride Add-on Therapy in Schizophrenia Patients without Treatment Response to Second-generation Antipsychotics
por: Kang, Seung-Gul, et al.
Publicado: (2021)

Atypical antipsychotics as add-on treatment in late-life depression
por: Cakir, Sibel, et al.
Publicado: (2016)

Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium
por: Vázquez, Gustavo H., et al.
Publicado: (2021)

Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression
por: Katz, Eva G., et al.
Publicado: (2020)

Silexan for treatment of anxiety and depression in the context of COVID-19
por: Bartova, Lucie, et al.
Publicado: (2023)

Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations
por: Young, Allan H, et al.
Publicado: (2023)

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
por: Chen, Guang, et al.
Publicado: (2022)

Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials
por: Marini, Stefano, et al.
Publicado: (2016)

Successful Use of Add - On Topiramate for Antipsychotic - Induced Weight Gain
por: Shivakumar, Venkataram, et al.
Publicado: (2012)

Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia
por: Raveendranthan, Dhanya, et al.
Publicado: (2018)

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
por: Doherty, Teodora, et al.
Publicado: (2020)

PS75. Psychopharmacoepidemiology of Major Depressive Disorder in European Tertiary Psychiatric Treatment Centers
por: Bartova, Lucie, et al.
Publicado: (2016)

Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior
por: Canuso, Carla M., et al.
Publicado: (2021)

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

ESKALE study, a French real-world study of esketamine nasal spray for patients with treatment-resistant depression
por: Ludovic, S., et al.
Publicado: (2022)

Social determinants and distance from certified treatment centers are associated with initiation of esketamine nasal spray among patients with challenging-to-treat major depressive disorder
por: Liberman, Joshua, et al.
Publicado: (2023)

Managing dissociative symptoms following the use of esketamine nasal spray: a case report
por: Pereira, Sophia, et al.
Publicado: (2020)

Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
por: Castro, Meredith, et al.
Publicado: (2023)

Signalling by potassium: another second messenger to add to the list?
por: Shabala, Sergey
Publicado: (2017)

Add-on quetiapine in the treatment of major depressive disorder in elderly patients with cerebrovascular damage
por: Carta, Mauro Giovanni, et al.
Publicado: (2007)

To add or not to add a new treatment arm to a multiarm study: A decision‐theoretic framework
por: Lee, Kim May, et al.
Publicado: (2019)

A Comment on “Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia”
por: Naguy, Ahmed
Publicado: (2018)

ADD In The Workplace
por: Nadeau, Kathleen
Publicado: (2013)

Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials
por: Dold, Markus, et al.
Publicado: (2015)

Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression
por: Gałuszko-Węgielnik, Maria, et al.
Publicado: (2023)

Aerosolized antibiotics: do they add to the treatment of pneumonia?
por: Kollef, Marin H., et al.
Publicado: (2013)

Safinamide: an add-on treatment for managing Parkinson’s disease
por: Müller, Thomas
Publicado: (2018)

Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report
por: Vendrell-Serres, Júlia, et al.
Publicado: (2021)

Combining machine learning algorithms for prediction of antidepressant treatment response
por: Kautzky, Alexander, et al.
Publicado: (2020)

Valganciclovir as Add-on to Second-Line Therapy in Patients with Recurrent Glioblastoma
por: Pantalone, Mattia Russel, et al.
Publicado: (2022)

High Kynurenine (a Tryptophan Metabolite) Predicts Remission in Patients with Major Depression to Add-on Treatment with Celecoxib
por: Krause, Daniela, et al.
Publicado: (2017)

The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder
por: Bartova, Lucie, et al.
Publicado: (2021)

Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)
por: Ionescu, Dawn F, et al.
Publicado: (2020)

Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report
por: Bossaller, Nicholas A., et al.
Publicado: (2020)

Editorial: Add-on Tests
Publicado: (2006)

Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
por: Jones, Robyn R., et al.
Publicado: (2022)

Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
por: Zaki, Naim, et al.
Publicado: (2023)

Barriers to yoga therapy as an add-on treatment for schizophrenia in India
por: Baspure, Shubhangi, et al.
Publicado: (2012)

Topiramate Add-on Lithium Carbonate for Treatment of Acute Mania
por: Mirsepassi, Zahra, et al.
Publicado: (2013)

S47. ADD-ON SPIRONOLACTONE FOR THE TREATMENT OF SCHIZOPHRENIA (SPIRO TREAT)
por: Roeh, Astrid, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_npmjosarqmd6n409q9pgi37102